Literature DB >> 10758311

Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose-response.

M W Skwarchuk1, A Jackson, M J Zelefsky, E S Venkatraman, D M Cowen, S Levegrün, C M Burman, Z Fuks, S A Leibel, C C Ling.   

Abstract

PURPOSE: The purpose of this paper is to use the outcome of a dose escalation protocol for three-dimensional conformal radiation therapy (3D-CRT) of prostate cancer to study the dose-response for late rectal toxicity and to identify anatomic, dosimetric, and clinical factors that correlate with late rectal bleeding in multivariate analysis. METHODS AND MATERIALS: Seven hundred forty-three patients with T1c-T3 prostate cancer were treated with 3D-CRT with prescribed doses of 64.8 to 81.0 Gy. The 5-year actuarial rate of late rectal toxicity was assessed using Kaplan-Meier statistics. A retrospective dosimetric analysis was performed for patients treated to 70.2 Gy (52 patients) or 75.6 Gy (119 patients) who either exhibited late rectal bleeding (RTOG Grade 2/3) within 30 months after treatment (i.e., 70.2 Gy-13 patients, 75. 6 Gy-36 patients) or were nonbleeding for at least 30 months (i.e., 70.2 Gy-39 patients, 75.6 Gy-83 patients). Univariate and multivariate logistic regression was performed to correlate late rectal bleeding with several anatomic, dosimetric, and clinical variables.
RESULTS: A dose response for >/= Grade 2 late rectal toxicity was observed. By multivariate analysis, the following factors were significantly correlated with >/= Grade 2 late rectal bleeding for patients prescribed 70.2 Gy: 1) enclosure of the outer rectal contour by the 50% isodose on the isocenter slice (i.e., Iso50) (p < 0.02), and 2) smaller anatomically defined rectal wall volume (p < 0.05). After 75.6 Gy, the following factors were significant: 1) smaller anatomically defined rectal wall volume (p < 0.01), 2) higher rectal D(max) (p < 0.01), 3) enclosure of rectal contour by Iso50 (p < 0.01), 4) patient age (p = 0.02), and 5) history of diabetes mellitus (p = 0.04). In addition to these five factors, acute rectal toxicity was also significantly correlated (p = 0.05) with late rectal bleeding when patients from both dose groups were combined in multivariate analysis.
CONCLUSION: A multivariate logistic regression model is presented which describes the probability of developing late rectal bleeding after conformal irradiation of prostate cancer. Late rectal bleeding correlated with factors which may indicate that a greater fractional volume of rectal wall was exposed to high dose, such as smaller rectal wall volume, inclusion of the rectum within the 50% isodose on the isocenter slice, and higher rectal D(max).

Entities:  

Mesh:

Year:  2000        PMID: 10758311     DOI: 10.1016/s0360-3016(99)00560-x

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  51 in total

Review 1.  Radiation therapy dose escalation for prostate cancer: a rationale for IMRT.

Authors:  Alan Pollack; Alex Hanlon; Eric M Horwitz; Steven Feigenberg; Robert G Uzzo; Robert A Price
Journal:  World J Urol       Date:  2003-09-05       Impact factor: 4.226

2.  Interfractional fluctuation of rectal dose in high dose rate brachytherapy for prostate cancer.

Authors:  Hime Ishikawa; Morio Sato; Shintaro Shirai; Kazushi Kishi; Yoshitaka Naya; Hisaki Tokunaga
Journal:  Radiat Med       Date:  2006-11-24

3.  Incidence of late rectal bleeding in high-dose conformal radiotherapy of prostate cancer using equivalent uniform dose-based and dose-volume-based normal tissue complication probability models.

Authors:  Matthias Söhn; Di Yan; Jian Liang; Elisa Meldolesi; Carlos Vargas; Markus Alber
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-01-26       Impact factor: 7.038

4.  Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer.

Authors:  Phillip J Gray; Jonathan J Paly; Beow Y Yeap; Martin G Sanda; Howard M Sandler; Jeff M Michalski; James A Talcott; John J Coen; Daniel A Hamstra; William U Shipley; Stephen M Hahn; Anthony L Zietman; Justin E Bekelman; Jason A Efstathiou
Journal:  Cancer       Date:  2013-02-22       Impact factor: 6.860

5.  Highly cited German research contributions to the fields of radiation oncology, biology, and physics: focus on collaboration and diversity.

Authors:  C Nieder
Journal:  Strahlenther Onkol       Date:  2012-08-23       Impact factor: 3.621

Review 6.  Proton beam radiation therapy for prostate cancer-is the hype (and the cost) justified?

Authors:  Phillip J Gray; Jason A Efstathiou
Journal:  Curr Urol Rep       Date:  2013-06       Impact factor: 3.092

7.  Late rectal toxicity on RTOG 94-06: analysis using a mixture Lyman model.

Authors:  Susan L Tucker; Lei Dong; Walter R Bosch; Jeff Michalski; Kathryn Winter; Radhe Mohan; James A Purdy; Deborah Kuban; Andrew K Lee; M Rex Cheung; Howard D Thames; James D Cox
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-07-02       Impact factor: 7.038

8.  Planning target volume margins for prostate radiotherapy using daily electronic portal imaging and implanted fiducial markers.

Authors:  David Skarsgard; Pat Cadman; Ali El-Gayed; Robert Pearcey; Patricia Tai; Nadeem Pervez; Jackson Wu
Journal:  Radiat Oncol       Date:  2010-06-10       Impact factor: 3.481

Review 9.  Reducing rectal injury during external beam radiotherapy for prostate cancer.

Authors:  Riccardo Valdagni; Tiziana Rancati
Journal:  Nat Rev Urol       Date:  2013-05-14       Impact factor: 14.432

10.  Self-assessed bowel toxicity after external beam radiotherapy for prostate cancer--predictive factors on irritative symptoms, incontinence and rectal bleeding.

Authors:  Michael Pinkawa; Marc D Piroth; Karin Fischedick; Sandra Nussen; Jens Klotz; Richard Holy; Michael J Eble
Journal:  Radiat Oncol       Date:  2009-09-21       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.